We all wonder how the new CEO would shape the company. Would he sweep out the incompetent, or internally networked? Who would be the replacements? Roche and Genentech people with experience mismatch? Some candidates may be attracted by location coming from some dull, backwater places. However, internal management changes are needed.
Very good candidates cannot be attracted considering future product portfolio prospects. Therefore, a new team may be as inefficient as the old one. All under the excuse of working on ultrarare diseases. Really rare, like the 3 hemophilia patients so far. The Gates Foundation is more appropriate to work on such scale projects.
Top management needs to be replaced, followed by incompetent middle level.
The top managers have been useless preoccupied with how to protect their positions and at the same time minimizing their responsibilities. They could not manage the parts of organization they were put in charge of.
But watch who will be coming. Roche-Genentech buddies or transition opportunists including international travelers. The CEO to be watched.
Stock went up since investors realized what new ceo would.
He will fire people at all levels, close the plants, manufacture using cmo, reorganize research with more work by cro, sell the irelend operations, all to improve the company bottom line.
